Looking for Investment, Acquisition, Partnerships or Collaborations?

Hosting AbbVie, AZ, Biogen, J&J, Merck, Sanofi, Regeneron, Otsuka, and UCB, the Autoimmunity Pharma & Biotech Partnering Summit guarantees 30-minute, in-person meetings, to foster scientific partnerships across targeted cell depletion and immune tolerance.

Helping both biotech and pharma cut through the noise to enhance portfolios, drive external collaboration, and promote creative partnerships across early-stage innovation; this unique initiative is an intensely valuable 48 hours for business development across immunology.

EVENT IN NUMBERS

60+

attending companies across modalities so pharma can decide which horse to back in this quickly evolving space

15

big pharma leads across business development, search and evaluation, immunology research and venture giving the best, most comprehensive opportunity to meet the full teams assessing due diligence and asset synergy

1-2-1

meetings bookable via the partnering portal for efficient and high yielding conversations between decision makers

100%

alignment on interests and intentions, increasing the surface area for synergy in research and collaboration goals

Testimonials

“This was an intimate conference in an equally intimate setting - great for networking!”

Director, Search & Evaluation, Merck

“Being able to meet with many target Pharma representatives and have multiple conversations - as many as I would meet at BIO but would never see them again at the meeting for follow up or social networking.”

CEO, Oncology Biotech

Key Figures from Partnering Series

214

meetings through the partnering portal

24%

acceptance rate of meetings, versus 11% industry standard

106

total attendees, including: 23 pharma, 65 biotech

86

companies, including: 16 pharma, 58 biotech, 4 investors

41%

C-level, 57% Vice President or Above, 94% Director or above

Event Attendees

For biotech business development and corporate strategy

to collaborate together across modalities with potential for combinations, or co-develop with pharma to combine resources and confidently progress past proof-of-concept.

For pharma search and evaluation, business development, and corporate venture

to compare competing and complementary science across modalities in the context of scientific discussion, direct ongoing early development of high potential assets, and grow activity or pipelines in the hotly anticipated immune reset and reconstitution field.